MAGNESIUM SULFATE

By intravenous infusion. 9% w/v Sodium Chloride Injection given over a period of 12 – 24 hours. Patients with renal impairment, the dosage will need to be reduced.

In patients with impaired renal function there may be sufficient accumulation to produce toxic effects. Excessive administration of magnesium leads to the development of hypermagnesaemia. Symptoms of hypermagnesaemia may include nausea, vomiting, flushing of the skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, loss of tendon reflexes and respiratory depression due to neuromuscular blockade, muscle weakness, respiratory depression, cardiac arrhythmias, coma, and cardiac arrest.

Hypersensitivity reactions. Hypocalcaemia. 6). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Magnesium salts should be administered with caution to patients with impaired renal function; appropriate reductions in dosage should be made (Refer to ‘Posology and Method of Administration’ above). Parenteral magnesium should be used with caution in individuals with myasthenia gravis, to prevent an exacerbation of the condition or the precipitation of a myasthenic crisis.

A risk-benefit assessment should be performed in individual cases prior to initiation of treatment. Magnesium sulfate should not be used in hepatic coma if there is risk of renal failure. Serum calcium levels should be routinely monitored in patients receiving magnesium sulfate.

1. Hepatic encephalopathy, hepatic failure or renal failure. Parenteral magnesium salts should generally be avoided in patients suffering from heart block.